Sweden Transthyretin Amyloidosis Treatment Market Size & Outlook
Related Markets
Sweden transthyretin amyloidosis treatment market highlights
- The Sweden transthyretin amyloidosis treatment market generated a revenue of USD 68.0 million in 2024 and is expected to reach USD 166.9 million by 2030.
- The Sweden market is expected to grow at a CAGR of 13.6% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
- Targeted Therapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Transthyretin amyloidosis treatment market data book summary
| Market revenue in 2024 | USD 68.0 million |
| Market revenue in 2030 | USD 166.9 million |
| Growth rate | 13.6% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Targeted Therapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Supportive Therapy |
| Key market players worldwide | Pfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech |
Other key industry trends
- In terms of revenue, Sweden accounted for 1.0% of the global transthyretin amyloidosis treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany transthyretin amyloidosis treatment market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 738.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Transthyretin Amyloidosis Treatment Market Scope
Transthyretin Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| SOM Biotech | View profile | 11-50 | Barcelona, Catalonia, Spain, Europe | http://www.sombiotech.com/ |
| Acrotech BioPharma | View profile | 51-100 | Windsor, New Jersey, United States, North America | https://acrotechbiopharma.com/ |
| Prothena Corp PLC | View profile | 173 | 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Ireland, D02 VK60 | https://www.prothena.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| BridgeBio Pharma Inc | View profile | 556 | 3160 Porter Drive, Suite 250, Palo Alto, CA, United States, 94304 | https://www.bridgebio.com |
| Alnylam Pharmaceuticals Inc | View profile | 2100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | https://www.alnylam.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Sweden transthyretin amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 116.18% in 2024. Horizon Databook has segmented the Sweden transthyretin amyloidosis treatment market based on targeted therapy, supportive therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Sweden transthyretin amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Sweden transthyretin amyloidosis treatment market databook
-
Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden transthyretin amyloidosis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Sweden transthyretin amyloidosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Sweden transthyretin amyloidosis treatment market size, by therapy, 2018-2030 (US$M)
Sweden Transthyretin Amyloidosis Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
